Article

Lung Cancer Drug Delays Disease More Than a Year

An experimental lung cancer pill from AstraZeneca delays disease progression by more than a year, according to new data presented at European Lung Cancer Conference.

An experimental lung cancer pill from AstraZeneca delays disease progression by more than a year, according to new data presented at a medical meeting on Friday.

AZD9291, which the company expects to file for US approval in the second quarter of 2015, is one of a number of cancer medicines AstraZeneca is hoping will rebuild its sales following patent losses on older drugs.

An analysis presented at the European Lung Cancer Conference in Geneva demonstrated a median progression-free survival for patients on the drug of 13.5 months.

Read more at Reuters: http://reut.rs/1Q1Dm4n

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
CK Wang, MD, COTA
Eric Lander, MD
Eric Lander, MD
David Awad, PharmD, BCOP
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo